Mercer Global Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Mercer Global Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.1M	Sell	13,257 -1,093	-8%	-$148K	﹤0.01%	1304
2026 Q1	$1.83M	Buy	14,350 +1,157	+9%	+$144K	﹤0.01%	1232
2025 Q4	$1.61M	Sell	13,193 -2,337	-15%	-$268K	﹤0.01%	1218
2025 Q3	$1.56M	Buy	15,530 +4,086	+36%	+$368K	﹤0.01%	1147
2025 Q2	$949K	Sell	11,444 -5,047	-31%	-$403K	﹤0.01%	1251
2025 Q1	$1.34M	Buy	16,491 +3,751	+29%	+$335K	﹤0.01%	990
2024 Q4	$1.15M	Buy	12,740 +1,651	+15%	+$160K	﹤0.01%	1042
2024 Q3	$1.09M	Sell	11,089 -39	-0.4%	-$3.83K	﹤0.01%	987
2024 Q2	$1.03M	Buy	11,128 +3,214	+41%	+$288K	﹤0.01%	954
2024 Q1	$749K	Buy	7,914 +1,169	+17%	+$108K	﹤0.01%	1083
2023 Q4	$602K	Sell	6,745 -120	-2%	-$8.91K	﹤0.01%	1214
2023 Q3	$501K	Sell	6,865 -1,575	-19%	-$126K	﹤0.01%	1251
2023 Q2	$702K	Buy	8,440 +435	+5%	+$36.4K	﹤0.01%	1082
2023 Q1	$610K	Sell	8,005 -1,732	-18%	-$144K	﹤0.01%	1105
2022 Q4	$808K	Buy	9,737 +2,622	+37%	+$212K	﹤0.01%	1003
2022 Q3	$564K	Buy	7,115 +1,038	+17%	+$87.5K	﹤0.01%	1078
2022 Q2	$451K	Sell	6,077 -3,934	-39%	-$295K	﹤0.01%	1198
2022 Q1	$900K	Buy	10,011 +1,113	+13%	+$103K	0.01%	940
2021 Q4	$996K	Buy	8,898 +60	+0.7%	+$7.24K	0.01%	885
2021 Q3	$1.11M	Sell	8,838 -1	-0%	-$129	0.01%	812
2021 Q2	$1.2M	Buy	8,839 +665	+8%	+$87.4K	0.01%	758
2021 Q1	$1.11M	Buy	8,174 +3,850	+89%	+$576K	0.01%	748
2020 Q4	$609K	Sell	4,324 -696	-14%	-$89.1K	0.01%	792
2020 Q3	$559K	Buy	5,020 +1,125	+29%	+$126K	0.01%	753
2020 Q2	$436K	Buy	3,895 +357	+10%	+$35.2K	0.01%	729
2020 Q1	$274K	Sell	3,538 -117	-3%	-$10.4K	0.01%	839
2019 Q4	$348K	Sell	3,655 -1,550	-30%	-$134K	0.01%	864
2019 Q3	$396K	Buy	5,205 +165	+3%	+$13.7K	0.01%	783
2019 Q2	$442K	Buy	5,040 +1,024	+25%	+$87.3K	0.01%	729
2019 Q1	$364K	Buy	+4,016	New	+$342K	0.01%	756

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Mercer Global Advisors's XBI Position: Q2 2026 in Review

Mercer Global Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 7.6% in Q2 2026, selling an estimated $148K and leaving 13,257 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Mercer Global Advisors first reported a position in XBI in Q1 2019 and has held it in 30 quarters since. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Mercer Global Advisors held 13,257 shares of State Street SPDR S&P Biotech ETF worth $2.1M as of Q2 2026.
Mercer Global Advisors sold 1,093 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $148K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1304 holding.
Mercer Global Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and has held it in 30 quarters since.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.